ArticleACS medicinal chemistry letters2015
Screening-based translation of public research encounters painful problems.
Article in ACS medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Isoxazole Derivative Induces Apoptosis-like Death and Autophagy through Oxidative Stress inACS omega · 2026Article
- Discovery and Characterization of a Selective Inhibitor of Synaptojanin1 5‑Phosphatase Activity.ACS pharmacology & translational science · 2025Article
- A Collection of Useful Nuisance Compounds (CONS) for Interrogation of Bioassay Integrity.JACS Au · 2024Article
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
- Genetic validation of Aspergillus fumigatus phosphoglucomutase as a viable therapeutic target in invasive aspergillosis.The Journal of biological chemistry · 2022Article
- On drug discovery against infectious diseases and academic medicinal chemistry contributions.Beilstein journal of organic chemistry · 2022Article
- Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands.Acta pharmaceutica Sinica. B · 2021Review
- Brief Guide: Experimental Strategies for High-Quality Hit Selection from Small-Molecule Screening Campaigns.SLAS discovery : advancing life sciences R & D · 2021Article
- Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential.Biomolecules · 2021Review
- Nuisance compounds in cellular assays.Cell chemical biology · 2021Review
- Bioprospecting for Antibacterial Drugs: a Multidisciplinary Perspective on Natural Product Source Material, Bioassay Selection and Avoidable Pitfalls.Pharmaceutical research · 2020Review
- A Review of the Antimalarial, Antitrypanosomal, and Antileishmanial Activities of Natural Compounds Isolated From Nigerian Flora.Frontiers in chemistry · 2020Review
- Resonant waveguide grating based assays for colloidal aggregate detection and promiscuity characterization in natural products.RSC advances · 2019Article
- Article
- Discorhabdin N, a South African Natural Compound, for Hsp72 and Hsc70 Allosteric Modulation: Combined Study of Molecular Modeling and Dynamic Residue Network Analysis.Molecules (Basel, Switzerland) · 2019Article
- Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs.ACS medicinal chemistry letters · 2018Article
- Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations.ACS chemical biology · 2018Review
- Computational modeling of the bat HKU4 coronavirus 3CLJournal of molecular recognition : JMR · 2017Article
- The Ecstasy and Agony of Assay Interference Compounds.ACS medicinal chemistry letters · 2017Article
- Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS.Journal of chemical information and modeling · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whether identified through high throughput screening or in silico screening, and whether target-based or phenotypic, sets of hits will contain chemical con artists. Such pan-assay interference compounds (PAINS) and other subversive compounds continue to pollute the scientific literature. There are several angles of attack to aid identification of such nonprogressable molecules. One of these rules above all, and this is a demonstration of genuine structure-activity relationships. Recognition of this, which will require a greater effort in medicinal chemistry, will be of general benefit.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.